HansBioMed is an innovative company that creates new possibilities through cutting-edge R&D technology. With a consistent annual growth rate of around 25% for the past five years, the company has achieved a stable financial position. HansBioMed is expanding its global business with seven overseas subsidiaries and branches worldwide.

Not only is HansBioMed involved in organizational engineering R&D, but it is also investing in R&D in the field of regenerative medicine and new medical technologies. The company aims to contribute to the health of humanity through these new ventures. Some notable achievements include being the first organization in Korea to receive permission to establish a tissue bank and receiving recognition from the US FDA for its state-of-the-art facilities for tissue transplantation research and production.

HansBioMed holds the distinction of being selected as a global leading product-certified company, representing the first venture company specializing in tissue transplantation products to be recognized as such. With its top-notch tissue engineering research facility, the company produces and researches various related products, including artificial breasts, skin grafts, and bone transplant products. With its listing on the KOSDAQ in 2009, HansBioMed secured skilled professionals and stable investment funds, propelling the company to become a true global player.

Its skin and bone transplantation products, developed as the first of their kind in Korea, are not only replacing foreign products but also being exported to regions around the world. With its commitment to technological advancement and a focus on improving global competitiveness in the tissue engineering industry, HansBioMed is dedicated to safeguarding national health and achieving import substitution